These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15697132)

  • 1. [Nonabsorbable disaccharides for the treatment of hepatic encephalopathy--a systemic review of randomized clinical trials--a secondary publication].
    Als-Nielsen BE; Gluud LL; Gluud CN
    Ugeskr Laeger; 2005 Jan; 167(2):179-82. PubMed ID: 15697132
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonabsorbable disaccharides for hepatic encephalopathy.
    Als-Nielsen B; Gluud LL; Gluud C
    Cochrane Database Syst Rev; 2004; (2):CD003044. PubMed ID: 15106187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonabsorbable disaccharides plus neomycin in hepatic encephalopathy: do they enhance each other?
    Capocaccia L; Riggio O
    Hepatology; 1990 Aug; 12(2):368-70. PubMed ID: 2391075
    [No Abstract]   [Full Text] [Related]  

  • 4. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides.
    Morgan MY
    Metab Brain Dis; 2016 Dec; 31(6):1361-1364. PubMed ID: 27638474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disaccharides in the treatment of hepatic encephalopathy.
    Sharma P; Sharma BC
    Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy.
    Patil DH; Westaby D; Mahida YR; Palmer KR; Rees R; Clark ML; Dawson AM; Silk DB
    Gut; 1987 Mar; 28(3):255-9. PubMed ID: 3570029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lactulose and its derivatives--treatment of hepatic encephalopathy and other possible indications for its use].
    Fehér J; Prónai L
    Orv Hetil; 1993 Jun; 134(26):1417-9. PubMed ID: 8332363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of hepatic encephalopathy.
    Morgan MY; Blei A; Grüngreiff K; Jalan R; Kircheis G; Marchesini G; Riggio O; Weissenborn K
    Metab Brain Dis; 2007 Dec; 22(3-4):389-405. PubMed ID: 17846875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.
    Als-Nielsen B; Gluud LL; Gluud C
    BMJ; 2004 May; 328(7447):1046. PubMed ID: 15054035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Portal systemic encephalopathy--should lactulose and neomycin be used together.
    Martin AJ
    Br J Clin Pract; 1981 Sep; 35(9):323-4. PubMed ID: 7326185
    [No Abstract]   [Full Text] [Related]  

  • 13. First and second generation non absorbable disaccharides in the treatment of hepatic encephalopathy.
    Capocaccia L; Riggio O; Merli M
    Ital J Gastroenterol; 1990 Dec; 22(6):365-7. PubMed ID: 2131958
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of lactulose and lactitol administration on fecal fat excretion in patients with liver cirrhosis.
    Merli M; Caschera M; Piat C; Pinto G; Diofebi M; Riggio O
    J Clin Gastroenterol; 1992 Sep; 15(2):125-7. PubMed ID: 1401823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial.
    Morgan MY; Hawley KE
    Hepatology; 1987; 7(6):1278-84. PubMed ID: 3315932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lactitol and neomycin: monotherapy or combined therapy in the prevention and treatment of hepatic encephalopathy?].
    Scevola D; Zambelli A; Concia E; Perversi L; Candiani C
    Clin Ter; 1989 Apr; 129(2):105-11. PubMed ID: 2525995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study.
    Orlandi F; Freddara U; Candelaresi MT; Morettini A; Corazza GR; Di Simone A; Dobrilla G; Cavallini G
    Dig Dis Sci; 1981 Jun; 26(6):498-506. PubMed ID: 7016484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of lactulose and neomycin in the treatment of porto-systemic encephalopathy].
    Sala Felis T; Berenguer J; Barrios JM; Gómez J
    Rev Esp Enferm Apar Dig; 1974 Feb; 42(3):335-42. PubMed ID: 4829021
    [No Abstract]   [Full Text] [Related]  

  • 19. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial.
    Atterbury CE; Maddrey WC; Conn HO
    Am J Dig Dis; 1978 May; 23(5):398-406. PubMed ID: 354373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis.
    Cammà C; Fiorello F; Tinè F; Marchesini G; Fabbri A; Pagliaro L
    Dig Dis Sci; 1993 May; 38(5):916-22. PubMed ID: 8482191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.